Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Posters

Search Title by author or title

The efficacy of topical tacrolimus ointment 0.03% as monotherapy for treatment of severe cases of vernal keratoconjunctivitis

Poster Details

First Author: N.El Zalitni LIBYA

Co Author(s):                        

Abstract Details

Purpose:

Purpose:- The aim of this study was to evaluate the efficacy of tacrolimus ointment 0.03% as monotherapy for treatment of severe cases of vernal keratconjuctivitis .

Setting:

DAR EL TAMUS private ophthalmology clinic in Benghazi Libya.

Methods:

Methods:- A prospective observational study of 32 eyes for 16 patients was carried out from (01-01 2017) to (31-12- 2017) where all of them attend to DAR EL TAMUS private ophthalmology clinic in Benghazi Libya, to assess the clinical subjective ocular signs and the objective ocular symptoms of severe cases vernal keratocojunctivitis . Where they are treated only with tacrolimus ointment 0.03% applied to the conjunctiva sac once at night in each eye for consecutive 8 weeks, where the signs and symptoms of vernal keratocojunctivitis followed prospectively at 1st week, 1st month, 2nd month, 3rd month, 6th month,12th month.

Results:

Result:- By the end of 8th weeks there was dramatic relief in the total score of symptoms and signs from baseline were recorded at each visit and no need for farther treatment up to the end of this study period 12th months. No relevant adverse effects were reported except mild burning sensation.

Conclusions:

Conclusion:- Tacrolimus ointment 0.03% was well tolerated and effective as monotherapy in reducing the signs and symptoms of sever cases of vernal keratoconjuctival and a valuable treatment option for this condition that may substitute for steroids treatment with its adverse effect. Keywords:- Vernal keratoconjunctivitis,tacrolimus,monotherapy,topical immunosuppressant.

Financial Disclosure:

None

Back to Poster listing